News

Soliris (eculizumab) can safely be discontinued in children with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission, but close monitoring is necessary due to the possibility of aHUS recurrence, a recent study in the Arabian Gulf region highlights. The study found that more than 70% of…

Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…

Proteins called factor Ba and sC5b-9 measured in the blood and urine of people with atypical hemolytic uremic syndrome (aHUS) showed they are clinically useful to mark features of the condition, a study showed. Thrombomodulin, a marker of blood vessel damage, and the inflammatory indicator sTNF-RI, combined with factor…

Maintenance treatment with Soliris (eculizumab) every three to six weeks — instead of the standard two weeks — is sufficient to promote complement inhibition and disease remission in most adults with atypical hemolytic uremic syndrome (aHUS), a small study suggests. This extended-dosing regimen is linked to savings of…

Ultomiris (ravulizumab) was shown to efficiently manage atypical hemolytic uremic syndrome (aHUS) in a woman in her 30s who had received Soliris (eculizumab) for more than a decade following a kidney transplant, according to a recent case study. Researchers noted there had previously been only a single…

When treating atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab), the medication can be safely discontinued after the immune system disorder is in remission, a new study shows. Moreover, the results suggest that stopping Soliris, rather than continuing treatment indefinitely, can lead to substantial cost savings without notably…

Soliris (eculizumab) shows effectiveness in treating patients with atypical hemolytic uremic syndrome (aHUS) both with and without severe and life-threatening hypertension, or high blood pressure, a large retrospective study found. Further, the researchers noted, “the results confirm the high [worse] severity and poor prognosis of untreated aHUS,” with a…

COVID-19 was a strong trigger for relapses of atypical hemolytic uremic syndrome (aHUS) in two brothers who were genetically predisposed to the syndrome, a recent case study reports. In both cases, treatment with Soliris (eculizumab) was effective in alleviating symptoms when given in the early stages of…

A booster dose of Moderna’s COVID-19 vaccine appears to have triggered an exaggerated immune response in a 38-year-old woman, leading to the development of atypical hemolytic uremic syndrome (aHUS), a case study reported. Researchers stressed the importance of reporting serious side effects after a COVID-19 vaccine so as to…

A new mutation in the CD46 gene linked to recurrent atypical hemolytic uremic syndrome (aHUS) was identified in a 13-month-old girl, according to a case report from Denmark. As described in the report, the mutation affected the activity of the complement cascade — a part of the immune system…